Oct 22, 2020 / 09:00AM GMT
Toshiaki Itagaki - Chugai Pharmaceutical Co., Ltd. - CFO & EVP - Fin. & Acct., Corp. Communication, Purchasing, Dig. Strategy & IT Sol.
Good evening, ladies and gentlemen. This is Itagaki. I will start explaining the slides.
Please look at the second page. It is a financial overview. In the cumulative third quarter, revenue was JPY 576.5 billion. Operating income was JPY 231.9 billion, and both sales and income grew by double digits, which reached record highs for the fourth consecutive year.
Revenue performed generally well with a progress rate of 77.9% compared to the full year forecast. Operating income and quarterly income have been strong, exceeding 80%.
Before getting into the details of the financial results, I would like to touch upon some of the events that have occurred in the last 3 months. Please see the third page. It is a summary of business updates. The events listed in blue are related to the development pipeline.
ENSPRYNG was approved in the U.S. and launched in Japan in August. KADCYLA and Tecentriq have been approved for indication
Q3 2020 Chugai Pharmaceutical Co Ltd Earnings Call Transcript
Oct 22, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers